Please assess the completion status of the following clinical trial:

Trial Title: Platelet Reactivity After TAVI: A Multicenter Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For inclusion in the study subjects should fulfill the following criteria:~1. Provision of informed consent prior to any study specific procedures.~2. Adult patients (more than 18 years) with ability to understand and accept the participation in the clinical trial.~3. Patients with degenerative symptomatic severe AS accepted for TAVI after evaluation of the Heart Team of each center.~4. Patients who are not participating in any other clinical trial or research study (registries allowed).~Exclusion Criteria:~Subjects should not enter the study if any of the following exclusion criteria are fulfilled:~1. Recent stroke \<14 days prior to TAVI, non-revascularized severe coronary or carotid artery disease (\>70% stenosis) or life expectancy \< 12 months~2. Patients under chronic oral anticoagulation~3. Patients with proven allergy to aspirin, clopidogrel or ticagrelor~4. Patients that after TAVI cannot undergo a regimen of single or dual antiplatelet therapy for 3 months due to a new post-TAVI medical indication~5. Known pregnancy or breast-feeding~6. Concomitant oral or intravenous therapy with potent inhibitors of cytochrome P450 3A (CYP3A) that cannot be suspended during the course of the study. Medications considered as potent inhibitors are: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin (or erythromycin but not astromicin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and more than a daily liter of grapefruit juice.~7. Thrombocytopenia (\<50,000 platelets U/L) well documented and clinically relevant.~8. Patients with documented moderate or severe hepatic insufficiency~9. Any condition that may put the patient at risk or influence the outcome of the trial~10. Patients previously randomized in this trial or in another clinical trial with an investigational product or device over the past 30 days.~11. Patients who cannot attend follow up visits scheduled in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
- Aspirin/Clopidogrel (Type: ACTIVE_COMPARATOR): Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
- Registry arm (Type: NO_INTERVENTION): Patients with normal-on-treatment platelet reactivity (PRU \< 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.

Based on this trial design, predict the completion outcome and termination type (if applicable).